Ruxolitinib Plus Capecitabine May Improve Survival in Pancreatic Cancer

Share this content:
Ruxolitinib plus capecitabine may improve survival in patients with metastatic pancreatic cancer and systemic inflammation.
Ruxolitinib plus capecitabine may improve survival in patients with metastatic pancreatic cancer and systemic inflammation.

Ruxolitinib plus capecitabine may improve survival in patients with metastatic pancreatic cancer, according to a study published online ahead of print in the Journal of Clinical Oncology.1

In a double-blind phase 2 study, researchers sought to determine whether patients with advanced pancreatic adenocarcinoma who had treatment failure with gemcitabine would benefit from the JAK1/JAK2 inhibitor ruxolitinib (15 mg twice daily) plus capecitabine (1,000 mg/m2) or placebo plus capecitabine.

In the intent-to-treat population (ruxolitinib, n=64; placebo, n=63) hazard ration was 0.79 (95% CI: 0.53 to 1.18; P=0.25) for overall survival and 0.75 (95% CI: 0.52 to 1.10; P=0.14) for progression-free survival.

A prespecified  subgroup analysis of patients with inflammation, defined by serum C-reactive protein levels greater than the study population median (13 mg/L), overall survival was significantly greater with ruxolitinib than with placebo (hazard ratio, 0.47; 95% CI:  0.26-0.85; P = 0.011).

RELATED: Addition of Rigosertib Fails to Improve Survival in Pancreatic Cancer

Prolonged survival in this subgroup was supported by post hoc analyses of overall survival that categorized patients by the modified Glasgow Prognostic Score. Ruxolitinib plus capecitabine was generally well tolerated.

In regard to safety, grade 3 or greater adverse events were observed with similar frequency in the ruxolitinib (74.6%) and placebo (81.7%) groups. Grade 3 or greater anemia was more frequent with ruxolitinib (15.3%; placebo, 1.7%).

Reference

  1. Hurwitz HI, Uppal N, Wagner SA, et al. Randomized, double-blind phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. [published online ahead of print September 8, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.61.4578.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters